Two Science sub-journals have shown that IgA antibodies dominate early response to SARS-CoV-2 coronavirus and are more effective in mediating the virus

December 11, 2020 /--- In a new study of more than 150 COVID-19 patients, researchers from several French research institutions found that IgA antibodies dominated early responses to SARS-CoV-2 coronavirus, faster and stronger than IgG and IgM antibodies.
this is a somewhat unexpected result because IgM antibodies are usually the first responders to the immune system.
could also provide information for the development of vaccines that trigger IGA reactions and for the development of IGA-based testing methods to detect infections at an early stage.
results were published online December 7, 2020 in the journal Translational Medicine under the title "IgA dominates the early neutralizing antibody response to SARS-CoV-2".
Gorochov, author of the paper's newsletter.
thymos cell dynamics after SARS-CoV-2 infection, pictured is Science Translational Medicine, 2020, doi:10.1126/scitranslmed.abd2223.
Gorochov and his team measured antibody responses in blood, saliva and bronchid-alveo cleaning fluid samples from these patients, who had varying symptoms of the disease.
they found that IgA concentrations in these samples were higher than IgG and IgM within 3 to 4 weeks of the first symptoms, and then gradually weakened, but IgA persisted in saliva for several weeks.
surge in IgA is associated with an increase in IGA secretion cells called plasmablast, which can target the surface of the respiratory mucous membranes attacked by the coronavirus.
they also found that IgA was more effective than IgG in terms of medium and SARS-CoV-2.
a new, unrelated study, researchers from Rockefeller University in the United States looked closely at the IGA response of 149 COVID-19 recoverers to SARS-CoV-2.
results were published online December 7, 2020 in the journal Science Science Medical under the title "Enhanced SARS-CoV-2 Neutralization by Dimeric IgA".
author of the paper is Professor Michel C. Nussenzweig of Rockefeller University.
After cloning antibodies extracted from these patients, Nussenzweig and his team found that IgA--- in the form of a djumer is formed by two IgA molecules connected together--- and is about 15 times more effective at mesolytic SARS-CoV-2 coronavirus than in the IgA monomer form.
IgA is generally considered to be the most common type of antibody in the mucous membrane tissue of the upper respiratory tract, which is the main entry point for the coronavirus.
Given the pot antibody's effectiveness, the Nussenzweig team believes that a vaccine designed to induce the production of the dijugaly IgA may be delivered to the target mucosa tissue by oral or nasal cavity, potentially protecting people from the coronavirus.
(Bioon.com) Reference: 1.Delphine Sterlin et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Science Translational Medicine, 2020, doi:10.1126/scitranslmed.abd2223.2.Zijun Wang et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2020, doi:10.1126/scitranslmed.abf1555.3.Two new studies investigate the early, potent response of IgA antibodies against SARS-CoV-2。